Evidence map›Paper›PMID 34371163›Full record

Trial reportContemporary clinical trials2021

Design of the Healthcare Worker Exposure Response and Outcomes (HERO) research platform.

Anne Friedland, Adrian F Hernandez, Kevin J Anstrom, Mei Lin Chen-Lim, Lauren W Cohen, Judith S Currier, Christopher B Forrest, Ryan Fraser, Elizabeth Fraulo, Anoop George and 20 more

Open access · greenAbstract readMulticenter StudyRandomized Controlled TrialPragmatic Clinical Trial
In one paragraph

Trial report in Contemporary clinical trials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Digital health-high tech or high touch?Wiener medizinische Wochenschrift (1946) · 2023
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors at 9 institutions in 1 country.

Anne FriedlandDuke Clinical Research Institute, Duke University, Durham, NC, United States of America.
Adrian F HernandezDuke Clinical Research Institute, Duke University, Durham, NC, United States of America.
Kevin J AnstromDuke Clinical Research Institute, Duke University, Durham, NC, United States of America.
Mei Lin Chen-LimChildren's Hospital of Philadelphia, Philadelphia, PA, United States of America.
Lauren W CohenDuke Clinical Research Institute, Duke University, Durham, NC, United States of America.
Judith S CurrierUniversity of California Los Angeles, Los Angeles, CA, United States of America.
Christopher B ForrestChildren's Hospital of Philadelphia, Philadelphia, PA, United States of America.
Ryan FraserDuke Clinical Research Institute, Duke University, Durham, NC, United States of America.
Elizabeth FrauloDuke Clinical Research Institute, Duke University, Durham, NC, United States of America.
Anoop GeorgeTemple University Hospital, Philadelphia, PA, United States of America.
Eileen HandbergUniversity of Florida, Gainesville, FL, United States of America.
Jennifer JackmanDuke Clinical Research Institute, Duke University, Durham, NC, United States of America.
Jayne KoellhofferDoylestown Health, Doylestown, PA, United States of America.
Daryl LawrenceVanderbilt University Medical Center, Nashville, TN, United States of America.
Renee LevertyDuke Clinical Research Institute, Duke University, Durham, NC, United States of America.
Patty McAdamsDuke Clinical Research Institute, Duke University, Durham, NC, United States of America.
Brian McCourtDuke Clinical Research Institute, Duke University, Durham, NC, United States of America.
Brenda MickleyDuke Clinical Research Institute, Duke University, Durham, NC, United States of America.
Syed Hasan NaqviUniversity of Missouri, Columbia, MO, United States of America.
Emily C O'BrienDuke Clinical Research Institute, Duke University, Durham, NC, United States of America.
Rachel OlsonDuke Clinical Research Institute, Duke University, Durham, NC, United States of America.
Clyde PraterWilliamson Medical Center, Franklin, TN, United States of America.
Russell L RothmanVanderbilt University Medical Center, Nashville, TN, United States of America.
Elizabeth ShenkmanDoylestown Health, Doylestown, PA, United States of America.
Jack ShostakDuke Clinical Research Institute, Duke University, Durham, NC, United States of America.
Kisha Batey TurnerVanderbilt University Medical Center, Nashville, TN, United States of America.
Laura WebbDuke Clinical Research Institute, Duke University, Durham, NC, United States of America.
Chris WoodsDuke Clinical Research Institute, Duke University, Durham, NC, United States of America.
Susanna NaggieDuke Clinical Research Institute, Duke University, Durham, NC, United States of America. Electronic address: Susanna.naggie@duke.edu.
HERO Research Program
Clinical Research Institute · USDuke University · USChildren's Hospital of Philadelphia · USVanderbilt University Medical Center · USDoylestown Hospital · USTemple University Hospital · USUniversity of California, Los Angeles · USUniversity of Florida · USUniversity of Missouri · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe SARS CoV-2 virus has caused one of the deadliest pandemics in recent history, resulting in over 170 million deaths and global economic disruption. There remains an urgent need for clinical trials to test therapies for treatment and prevention.

designAn online research platform was created to support a registry community of healthcare workers (HCWs) to understand their experiences and conduct clinical studies to address their concerns. The first study, HERO-HCQ, was a double-blind, multicenter, randomized, pragmatic trial to evaluate the superiority of hydroxychloroquine (HCQ) vs placebo for pre-exposure prophylaxis (PrEP) of COVID-19 clinical infection in HCWs. Secondary objectives were to assess the efficacy of HCQ in preventing viral shedding of COVID-19 among HCWs and to assess the safety and tolerability of HCQ.

methodsHCWs joined the Registry and were pre-screened for trial interest and eligibility. Trial participants were randomized 1:1 to receive HCQ or placebo. On-site baseline assessment included a COVID-19 nasopharyngeal PCR and blood serology test. Weekly follow-up was done via an online portal and included screening for symptoms of COVID-19, self-reported testing, adverse events, and quality of life assessments. The on-site visit was repeated at Day 30. DISCUSSION: The HERO research platform offers an approach to rapidly engage, screen, invite and enroll into clinical studies using a novel participant-facing online portal interface and remote data collection, enabling limited onsite procedures for conduct of a pragmatic clinical trial. This platform may be an example for future clinical trials of common conditions to enable more rapid evidence generation.

Indexed as

COVID-19Quality of LifeHealth PersonnelHumansSARS-CoV-2Treatment OutcomeCOVID-19Healthcare workersHydroxychloroquinePragmatic trialRegistryStudy platform

Identifiers

PMID34371163
PMCPMC8349387
OpenAlexW3190635942

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.